Comparative Pharmacology
Head-to-head clinical analysis: CLOROTEKAL versus TRANXENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOROTEKAL versus TRANXENE.
CLOROTEKAL vs TRANXENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.
Benzodiazepine; enhances GABA-A receptor activity by binding to benzodiazepine site, increasing chloride ion influx and neuronal hyperpolarization.
500 mg orally every 8 hours for 7-14 days.
7.5 mg to 15 mg orally 2 to 4 times daily; maximum dose 90 mg/day.
None Documented
None Documented
Terminal elimination half-life: 3.5 hours (range 2.5–4.5 h) in patients with normal renal function; prolonged to 12–18 h in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Terminal elimination half-life of the active metabolite desmethyldiazepam is 30-200 hours (mean ~100 hours); parent drug clorazepate is rapidly hydrolyzed and has negligible half-life. Accumulation occurs with repeated dosing, leading to delayed peak effects and prolonged sedation.
Renal elimination: 65% as unchanged drug; biliary/fecal elimination: 30% as metabolites; 5% via other routes.
Primarily renal (80-90% as conjugated metabolites, including oxazepam and desmethyldiazepam); biliary/fecal excretion accounts for <10%.
Category C
Category C
Benzodiazepine Anxiolytic
Benzodiazepine Anxiolytic